

10/513699

## Connecting via Winsock to STN

LOGINID:  
SSPTAEAL1624

STNLOGON timed out

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

10/513699

NEWS 26 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary  
NEWS 27 DEC 17 CA/CAPLUS enhanced with new custom IPC display formats  
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content  
from USPATOLD  
NEWS 29 JAN 02 STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:12:09 ON 15 JAN 2008

=> file reg  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY  
SESSION  
0.21  
0.21  
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:12:52 ON 15 JAN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1  
DICTIONARY FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

10/513699

=>  
Uploading C:\Program Files\Stnexp\Queries\10561747.str



chain nodes :  
7 8 9 10 11 12 13 14 15 16 17 19 20 21  
31 32 33 34

ring nodes :  
1 2 3 4 5 6

chain bonds :  
1-29 1-30 2-20 3-31 3-32 4-33 4-34 5-7 6-27 6-28 7-8 7-16 7-17 8-9  
8-24 8-25 9-10 9-19 9-26 10-11 10-14 11-12 11-13 14-15 20-21 21-23

ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :  
1-2 1-6 2-3 2-20 3-4 4-5 5-6 5-7 7-8 7-16 7-17 9-10 9-19 10-11 10-14  
11-12 20-21 21-23

exact bonds :  
1-29 1-30 3-31 3-32 4-33 4-34 4-34 6-27 6-28 8-9 8-24 8-25 9-26 11-13 14-15

isolated ring systems :  
containing 1 :

G1:Cy,Ak

G2:Cb,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS  
20:Atom 21:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

10/513699

L1 STRUCTURE UPLOADED

=> s 11 full1

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s 11 full

FULL SEARCH INITIATED 18:13:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 837 TO ITERATE

100.0% PROCESSED 837 ITERATIONS 51 ANSWERS  
SEARCH TIME: 00.00.01

L2 51 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

FULL ESTIMATED COST

178.82

SESSION

179.03

FILE 'CAPLUS' ENTERED AT 18:13:55 ON 15 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jan 2008 VOL 148 ISS 3

FILE LAST UPDATED: 14 Jan 2008 (20080114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 full

L3 3 L2

=> d ibib abs hitstr tot

<12/04/2007>

Erich Leese


10/513699


<12/04/2007>

Erich Leese

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:630134 CAPLUS  
 DOCUMENT NUMBER: 145:103718  
 TITLE: Preparation of (piperazinylsulfonylmethyl)alkynyl hydroxamates and analogs as matrix metalloprotease inhibitors and medical uses thereof  
 INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gerber, Patrick; Jorand-Lebrun, Catherine  
 PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles  
 SOURCE: PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067114	A1	20060629	WO 2005-EP56910	20051219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005318163	A1	20060629	AU 2005-318163	20051219
CA 2589367	A1	20060629	CA 2005-2589367	20051219
EP 1828160	A1	20070905	EP 2005-826371	20051219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
KR 2007095950	A	20071001	KR 2007-716256	20070716
PRIORITY APPLN. INFO.:			EP 2004-106814	A 20041221
			US 2004-638257P	P 20041222
			WO 2005-EP56910	W 20051219
OTHER SOURCE(S):	MARPAT 145:103718			
GI				






RN 895573-54-3 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(3-pyridinyl)-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895573-58-7 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(3-methoxyphenyl)-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895573-63-4 CAPLUS


CN Piperazine, 1-[(5-(diethylamino)-2-(formylhydroxyamino)-3-pentynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



10/513699


RN 895573-92-9 CAPLUS

CN Piperazine, 1-[2-(formylhydroxyamino)-4-phenyl-3-butynyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895573-94-1 CAPLUS

CN Piperazine, 1-[2-(formylhydroxyamino)-3-nonyl]sulfonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895574-00-2 CAPLUS

CN Piperazine, 1-[2-(formylhydroxyamino)-3-nonyl]sulfonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895574-01-3 CAPLUS

CN Piperazine, 1-[2-(formylhydroxyamino)-3-nonyl]sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895574-08-0 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-3-nonynyl)sulfonyl]-4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 895574-16-0 CAPLUS

CN Piperazine, 1-(4-ethoxyphenyl)-4-[(2-(formylhydroxyamino)-3-nonynyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 895574-21-7 CAPLUS


CN Piperazine, 1-[(2-(formylhydroxyamino)-4-phenyl-3-butynyl)sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 895574-24-0 CAPLUS


10/513699

CN Piperazine, 1-(4-ethoxyphenyl)-4-[(2-(formylhydroxyamino)-4-phenyl-3-butynyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 895574-30-8 CAPLUS

CN Piperazine, 1-(4-ethoxyphenyl)-4-[(2-(formylhydroxyamino)-3,3-dimethyl-6-phenyl-5-hexynyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 895574-31-9 CAPLUS

CN Piperazine, 1-(3,4-dimethoxyphenyl)-4-[(2-(formylhydroxyamino)-3-nonynyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:



2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:14380 CAPLUS  
 DOCUMENT NUMBER: 142:114099  
 TITLE: Preparation of N-[ (4-substituted piperazine-1-sulfonylmethyl)alkyl]-N-hydroxyformamides as metalloproteinase inhibitors  
 INVENTOR(S): Finlay, Maurice Raymond Verschoyle; Waterson, David  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000822	A1	20050106	WO 2004-GB2702	20040623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004251104	A1	20050106	AU 2004-251104	20040623
CA 2529468	A1	20050106	CA 2004-2529468	20040623
EP 1644340	A1	20060412	EP 2004-743053	20040623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812974	A	20060802	CN 2004-80018244	20040623
BR 2004011929	A	20060815	BR 2004-11929	20040623
JP 2007516164	T	20070621	JP 2006-516467	20040623
MX 2005PA13460	A	20060309	MX 2005-PA13460	20051209
US 2007197542	A1	20070823	US 2005-561747	20051221
NO 2006000444	A	20060322	NO 2006-444	20060127
PRIORITY APPLN. INFO.:			SE 2003-1922	A 20030627
			WO 2004-GB2702	W 20040623

OTHER SOURCE(S): MARPAT 142:114099  
 GI



AB The title compds. I [ring B = monocyclic aryl ring having six ring atoms or a monocyclic heteroaryl ring having up to six ring atoms and containing one or more ring heteroatoms wherein each said heteroatom is nitrogen; R2 = alkyl or aryl, which said group is substituted by one or more fluorine groups; n = 1-3; R1 = (un)substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl-aryl, alkyl-heteroaryl, alkyl-cycloalkyl or alkyl-heterocycloalkyl], useful in the treatment of a disease condition mediated by one or more metalloproteinase enzymes, were prepared E.g., a multi-step synthesis of (S)-II, starting from 5-ido-2-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine, was given. In general, the compds. I demonstrate IC50 values in the range of 0.01 to 1000 nM against collagenase 3. The pharmaceutical composition comprising the compound I is disclosed.

IT 823197-00-8P 823197-01-9P 823197-02-0P  
 823197-03-1P 823197-04-2P 823197-05-3P  
 823197-06-4P 823197-07-5P 823197-08-6P  
 823197-09-7P 823197-10-0P 823197-11-1P  
 823197-12-2P 823197-13-3P 823197-14-4P  
 823197-15-5P 823197-16-6P 823197-17-7P  
 823197-18-8P 823197-19-9P 823197-20-2P  
 823197-21-3P 823197-22-4P 823197-23-5P  
 823197-24-6P 823197-25-7P 823197-26-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[(4-substituted piperazine-1-sulfonylmethyl)alkyl]-N-hydroxyformamides as metalloproteinase inhibitors)

RN 823197-00-8 CAPLUS


CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 823197-01-9 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl)sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 823197-02-0 CAPLUS

CN Piperazine, 1-[(4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl)sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 823197-03-1 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl)sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 823197-04-2 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 823197-05-3 CAPLUS

CN Piperazine, 1-[(4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 823197-06-4 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/513699

RN 823197-07-5 CAPLUS


CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-08-6 CAPLUS


CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl)sulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 823197-09-7 CAPLUS

CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 823197-10-0 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN Piperazine, 1-[(2-(formylhydroxyamino)-2-phenylethyl)sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-11-1 CAPLUS


CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl)sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-12-2 CAPLUS


CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentylsulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-13-3 CAPLUS


CN Piperazine, 1-[(4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl)sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-14-4 CAPLUS


CN Piperazine, 1-[(2S)-4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-15-5 CAPLUS


CN Piperazine, 1-[(2S)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-16-6 CAPLUS


CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 823197-17-7 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)butyl)sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 823197-18-8 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)propyl)sulfonyl]-4-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-19-9 CAPLUS


CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl)sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 823197-20-2 CAPLUS


CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-4-(2-pyrimidinyl)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-21-3 CAPLUS


CN Piperazine, 1-[(4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 823197-22-4 CAPLUS

CN Piperazine, 1-[(2S)-4-(5-fluoro-2-pyrimidinyl)-2-(formylhydroxyamino)butyl]sulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 823197-23-5 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentylsulfonyl)-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 823197-24-6 CAPLUS  
 CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentylsulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 823197-25-7 CAPLUS  
 CN Piperazine, 1-[(2S)-2-(formylhydroxyamino)-2-(tetrahydro-2H-pyran-4-yl)ethylsulfonyl]-4-[4-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 823197-26-8 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentylsulfonyl]-4-[5-(2,2,2-trifluoroethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:161258 CAPLUS  
 DOCUMENT NUMBER: 132:207849  
 TITLE: Preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP)  
 INVENTOR(S): Barlaam, Bernard Christophe; Newcombe, Nicholas John;  
 Tucker, Howard; Waterson, David  
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma Sa  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012478	A1	20000309	WO 1999-GB2801	19990825
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339761	A1	20000309	CA 1999-2339761	19990825
AU 9955247	A	20000321	AU 1999-55247	19990825
AU 764367	B2	20030814		
BR 9913255	A	20010522	BR 1999-13255	19990825
EP 1109787	A1	20010627	EP 1999-941751	19990825
EP 1109787	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200100605	T2	20010821	TR 2001-605	19990825
HU 2001003344	A2	20020228	HU 2001-3344	19990825
HU 2001003344	A3	20020328		
EE 200100106	A	20020617	EE 2001-106	19990825
JP 2002523493	T	20020730	JP 2000-567511	19990825
NZ 509730	A	20030530	NZ 1999-509730	19990825
RU 2220967	C2	20040110	RU 2001-108591	19990825
NZ 524921	A	20041029	NZ 1999-524921	19990825
AT 326448	T	20060615	AT 1999-941751	19990825
PT 1109787	T	20060929	PT 1999-941751	19990825
ES 2263284	T3	20061201	ES 1999-941751	19990825
TW 240722	B	20051001	TW 1999-88114833	19990830
ZA 2001001231	A	20020513	ZA 2001-1231	20010213
MX 2001PA01847	A	20020408	MX 2001-PA1847	20010220
US 6734184	B1	20040511	US 2001-763709	20010226
KR 771454	B1	20071031	KR 2001-702457	20010226
NO 2001001023	A	20010425	NO 2001-1023	20010228
NO 321478	B1	20060515		
BG 105369	A	20011231	BG 2001-105369	20010322
HK 1036060	A1	20061027	HK 2001-106732	20010924
AU 2003262101	A1	20031218	AU 2003-262101	20031112
US 2004171641	A1	20040902	US 2004-787775	20040226
PRIORITY APPLN. INFO.:			EP 1998-402144	A 19980831

EP 1999-401351 A 19990604  
 WO 1999-GB2801 W 19990825  
 US 2001-763709 A1 20010226

OTHER SOURCE(S):  
 GI

MARPAT 132:207849




AB The title compds. [I; B = monocyclic or bicyclic alkyl, aryl, etc.; R3 = H, halo, NO<sub>2</sub>. etc.; n = 1-3; P = (CH<sub>2</sub>)<sub>n</sub> (wherein n = 0-2), alkene, alkyne, etc.; A = (un)substituted 5-7 membered aliphatic ring; X<sub>1</sub>, X<sub>2</sub> = N, C, where a ring substituent on ring A is a oxo group that is preferably adjacent a ring N atom; Y = SO<sub>2</sub>, CO; Z = CONHOH, Y = CO and Q = CR<sub>6</sub>R<sub>7</sub>, CR<sub>6</sub>R<sub>7</sub>CH<sub>2</sub>, NR<sub>6</sub>, NR<sub>6</sub>CH<sub>2</sub> (wherein R<sub>6</sub> = H, alkyl, aralkyl, etc.; R<sub>7</sub> = H, alkyl; R<sub>7</sub> together with R<sub>6</sub> forms a carbocyclic or heterocyclic spiro 5-7 membered ring, the latter containing at least one heteroatom selected from N, O, S); Z = CONHOH, Y = SO<sub>2</sub> and Q = CR<sub>6</sub>R<sub>7</sub>, CR<sub>6</sub>R<sub>7</sub>CH<sub>2</sub>; Z = N(OH)CHO and Q = CHR<sub>6</sub>, CHR<sub>6</sub>CH<sub>2</sub>, NR<sub>6</sub>CH<sub>2</sub>; R<sub>1</sub> = H, alkyl, cycloalkyl, etc.; R<sub>2</sub> = H, alkyl, aryl, etc.], useful as metalloproteinase inhibitors (no data), especially as inhibitors of MMP 13, in treating arthritis and atherosclerosis, were prepared E.g., a multi-step synthesis of the title piperazine II was given. Compds. I are effective at 0.5-30 mg/kg/day.

IT 260439-08-5P 260439-96-1P 260440-00-4P  
 260440-21-9P 260441-00-7P 260441-01-8P  
 260441-02-9P 260441-03-0P 260441-04-1P  
 260441-05-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP))

RN 260439-08-5 CAPLUS


CN Piperazine, 1-[(2-(formylhydroxyamino)-4-phenylbutyl)sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260439-96-1 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 260440-00-4 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 260440-21-9 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-2-phenylethyl]sulfonyl]-4-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 260441-00-7 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-3-(phenylmethoxy)propyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260441-01-8 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(2-pyridinyl)butyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260441-02-9 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-4-(3-pyridinyl)butyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-03-0 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-thienyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 260441-04-1 CAPLUS  
 CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyrimidinyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 260441-05-2 CAPLUS

CN Piperazine, 1-[(2-(formylhydroxyamino)-5-(2-pyridinyl)pentyl]sulfonyl]-4-(6-methoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

=> d his

(FILE 'HOME' ENTERED AT 18:12:09 ON 15 JAN 2008)

FILE 'REGISTRY' ENTERED AT 18:12:52 ON 15 JAN 2008

L1                   STRUCTURE UPLOADED  
L2                   51 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:13:55 ON 15 JAN 2008

L3                   3 S L2 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.71	210.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

STN INTERNATIONAL LOGOFF AT 18:33:01 ON 15 JAN 2008